Real-World Experience of Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Multiple Myeloma Relapsed/Refractory to Bortezomib and Lenalidomide
The weekly KCd regimen demonstrated encouraging efficacy and tolerability in a heavily pretreated RRMM population. These findings support its use as a feasible treatment option, particularly in patients refractory to lenalidomide.
Authors
- Ka‐Won Kang (ORCID: https://orcid.org/0000-0003-1462-0502)
- Seong Hyun Jeong
- Yoon Seok Choi (ORCID: https://orcid.org/0000-0002-0054-3641)
- Kunye Kwak (ORCID: https://orcid.org/0009-0005-5908-2607)
- Yong Bum Park (ORCID: https://orcid.org/0000-0002-5814-6104)
- Byung Soo Kim (ORCID: https://orcid.org/0000-0002-3657-8619)
- Joon Seong Park (ORCID: https://orcid.org/0000-0001-7999-0577)
- Changgon Kim
- Cheongin Yang
Institutions
- Korea University (KR)
- Ajou University (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2025-04-24
- DOI
- https://doi.org/10.4143/crt.2025.418
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea